Table 4.
CD8+ cell noncytotoxic anti-HIV suppression in HAART-treated and untreated subjects
| Extent of CD8+ cell suppression, % | Subject category | Week 0 | Week 4 | Week 12 | Week 24 |
|---|---|---|---|---|---|
| >50 | Treated | 16 of 21 (76%) | 4 of 9 (44%) | 8 of 15 (53%) | 8 of 21 (38%)* |
| Untreated | 3 of 5 (60%) | 4 of 4 (100%) | 5 of 5 (100%) | 5 of 5 (100%)** | |
| ≥90 | Treated | 8 of 21 (38%) | 2 of 9 (22%) | 7 of 15 (47%) | 5 of 21 (24%) |
| Untreated | 1 of 5 (20%) | 2 of 4 (50%) | 3 of 5 (60%) | 3 of 5 (60%) |
Values shown are the fraction and percentage of individuals whose CD8+ cells demonstrate >50% or ≥90% inhibition of HIV-1SF33 (CXCR4-tropic, β chemokine-resistant virus) replication in an acute infection assay. Inhibition of virus replication was assessed by evaluating RT levels in culture supernatants (see Materials and Methods) on days 3, 7, and 10 after infection. The final level of suppression was determined on the day of peak reverse transcriptase activity in wells containing only control infected CD4+ cells (typically 1 × 106 to 2 × 106 cpm/ml).
, P = 0.01 in comparing CD8+ cell anti-HIV response between week 0 and week 24 (McNemar's test);
, P = 0.04 in comparing treated and untreated subjects at week 24 (Fisher's exact test).